The prospects for long-term intervention in asthma with antileukotrienes

Clinical and Experimental Allergy, Supplement

Volumn 28, Issue 5, 1998, Pages 154-163

  Smith, L J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 2 [4 [2 (5 TETRAZOLYLMETHYL)BENZYLOXY]PHENOXYMETHYL]QUINOLINE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 CARBOXYPHENYLTHIO) 7 [4 (4 PHENOXYBUTOXY)PHENYL] 5 HEPTENOIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ACETYLSALICYLIC ACID; BAY X7159; CINALUKAST; DIGOXIN; ERYTHROMYCIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NAPROXEN; PHENYTOIN; PRANLUKAST; PREDNISONE; THEOPHYLLINE; UNCLASSIFIED DRUG; VERLUKAST; WARFARIN; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; FOOD DRUG INTERACTION; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LONG TERM CARE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROVOCATION TEST; VASCULITIS;

EID: 0031791426     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1998.028s5154.x     Document Type: Conference Paper

References (81)

1. Guidelines for the diagnosis, management of asthma. Expert Panel Report II. Bethesda, MD. National Institutes of Health 1997 NIH publication no. 97-4051.
2. Holgate S. Mediator and cytokine mechanisms in asthma. Thorax 1993; 48:103-9.
3. Smith LJ. Leukotrienes in asthma. Arch Int Med 1996; 156:2181-9.
4. 4-induced bronchoconstriction in normal subjects by the oral leukotriene receptor antagonist ICI 204,219. Am Rev Respir Dis 1990; 141:988-92.
5. 4-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 1995; 151:A378 (abstract).
6. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin Pharmacol Ther 1993; 54:430-6.
7. 4) challenge in normal volunteers. Thorax 1997; 52:519-22.
8. 4-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 1997; 99:S328 (abstract).
9. 4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997; 61:83-92.
10. 4-receptor antagonist. N Engl J Med 1990; 323:1736-9.
11. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Am Rev Respir Dis 1992; 145:746-9.
12. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147:1413-8.
13. 4-receptor antagonist, ICI 204,219, on cold-air-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 1993; 93:295A (abstract).
14. Boulet LP, Bai TR, Miller CJ et al. Effect of zafirlukast on cold-air-induced bronchoconstriction in patients with asthma. Eur Respir J 1996; 9 (Suppl. 23):272s (abstract).
15. Israel E, Lavins BJ, Miller CJ et al. Effect of zafirlukast (20 and 40 mg) on cold-air-induced bronchoconstriction in patients with bronchial asthma. Eur Respir J 1996; 9 (Suppl. 23):51s (abstract).
16. Suguro H, Majima T, Ichimura K et al. Effect of a leukotriene antagonist, pranlukast hydrate, on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1997; 155:A662 (abstract).
17. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther 1997; 62:556-61.
18. Leff JA, Bronsky EA, Kemp J et al. Montelukast (MK-0476) inhibits exercise-induced bronchoconstriction over 12 weeks without causing tolerance. Am J Respir Crit Care Med 1997; 155:A977 (abstract).
19. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996; 153:931-5.
20. Israel E, Dermarkarian R, Rosenberg M et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323:1740-4.
21. Fischer AR, McFadden CA, Frantz R et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 1995; 152:1203-7.
22. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992; 90:193-201.
23. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337:690-4.
24. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89:1040-5.
25. Dahlen B, Zetterstrom O, Bjorck T, Dahlén S-E. The leukotriene-antagonist ICI 204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994; 7:324-31.
26. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993; 147:1431-5.
27. Nathan RA, Glass M, Minkwitz MC. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994; 105:483-8.
28. Taniguchi Y, Tamura G, Honma M et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993; 92:507-12.
29. Hamilton AL, Faiferman I, Stober P, Watson PM, O'Byrne PM. Pranlukast (SB205312, ONO 1078), a leukotriene receptor antagonist, attenuates allergen-induced early and late phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. Eur Respir J 1997; 10 (Suppl. 25):419s (abstract).
30. Diamant Z, Timmers MC, van den Veen H et al. Effect of oral montelukast (MK-0476), a potent leukotriene receptor antagonist, on allergen-induced airway responses in asthmatic subjects. Am J Respir Crit Care Med 1996; 153:A346 (abstract).
31. Hui KP, Taylor IK, Taylor W et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46:184-9.
32. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK & F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144:957-8.
33. Dahlén B, Kumlin M, Margolskee DJ et al. The leukotriene-receptor antagonist, MK-0679, blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993; 6:1018-26.
34. Yamamoto H, Nagata M, Kuramitsu K et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994; 150:254-7.
35. Israel E, Fischer AR, Rosenberg MA et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148:1447-51.
36. Dahlén B, Margolskee DJ, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993; 48:1205-10.
37. Kuna P, Malstrom K, Dahlén S-E et al. Montelukast (MK-0476), a cysLT1 receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients. Am J Respir Crit Care Med 1997; 155:A975 (abstract).
38. Dahlén B, Nizankowska E, Szczeklik A et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:1187-94.
39. Lazarus SC, Wong HH, Watts MJ et al. The leukotriene receptor antagonist, zafirlukast, inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 1997; 156:1725-30.
40. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337:1062-3.
41. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992; 146:358-63.
42. 4 antagonist, MK-679. Am Rev Respir Dis 1993; 147:1442-6.
43. Welch MJ, Nelson HS, Paull BR, Smith JA, Feiss G, Tobey RE. Effect of RG 12525, a new leukotriene antagonist, on pulmonary function of asthmatic adults. Ann Allergy 1994; 72:348-52.
44. Reiss TF, Sorkness CA, Stricker W et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997; 52:45-8.
45. Israel E, Rubin P, Kemp JP et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Int Med 1993; 119:1059-66.
46. 4-receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150:618-23.
47. Fish JE, Kemp JP, Lockey RF et al. Zafirlukast improves symptomatic mild to moderate asthma: a 13-week multicenter study. Clin Ther 1997; 19:675-90.
48. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. Ann Int Med 1997; 126:177-83.
49. Barnes NC, Pujet J-C, International Study Group. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997; 52:523-7.
50. Grossman J, Faiferman I, Dubb JW et al. Results of the first U.S. double-blind, placebo-controlled multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997; 34:321-8.
51. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98:528-34.
52. Reiss TF, Chervinsky P, Dockhorn RJ et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Int Med 1998; 158:1213-20.
53. Knorr BA, Matz J, Bernstein JA et al. Montelukast (MK-0479) improves asthma over a 2-month treatment period in 6-to 14-year olds. Am J Respir Crit Care Med 1997; 155:A664 (abstract).
54. Israek E, Cohn J, Dube L et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. J Am Med Assoc 1996; 275:931-6.
55. Liu MC, Dube LM, Lancaster J et al. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996; 98:859-71.
56. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 or cromolyn sodium in patients with mild to moderate asthma. J Allergy Clin Immunol 1995; 97:388 (abstract).
57. 2 agonists. Eur Respir J 1997; 10 (Suppl. 25):419s (abstract).
58. Westbroek J, Pasma HR. The effect of inhaled fluticasone propionate (FP) 100 mcg bd compared with oral zafirlukast 20 mg bd on bronchial hyperresponsiveness in mild to moderate asthmatics. Eur Respir J 1997; 10 (Suppl. 25):243s (abstract).
59. 1 in patients with asthma: results of a 12-week multicenter study vs. Nedocromil Am J Respir Crit Care Med 1997; 155:A665 (abstract).
60. Wenzel S, Chervinsky P, Kerwin E et al. Oral pranlukast (Ultair) vs. inhaled beclomethasone: results of a 12-week trial in patients with asthma. Am J Respir Crit Care Med 1997; 155:A203 (abstract).
61. Tamaoki J, Kondo M, Sakai N et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155:1235-40.
62. Virchow JC, Hassall SM, Summerton L, Harris A. Improved asthma control over 6 weeks with Accolate (zafirlukast) in patients on high-dose inhaled corticosteroids. J Invest Med 1997; 45:286A.
63. 1 receptor antagonist, decreases peripheral blood eosinophils and improves signs and symptoms of asthma over a 3 month period. J Allergy Clin Immunol 1997; 99:5268.
64. Leff JA, Pizzichini E, Efthimiadis A et al. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 1997; 155:A977 (abstract).
65. Calhoun WJ, Lavins BJ, Minkwitz MC et al. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage findings. Am J Respir Crit Care Med 1998; 157:1381-9.
66. Wenzel SE, Trudeau JB, Kaminsky DA et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995; 152:897-905.
67. Manso G, Baker AJ, Taylor IK, Fuller RW. In vivo and in vitro effects of glucocorticosteroids on arachidonic acid metabolism and monocyte function in nonasthmatic humans. Eur Respir J 1992; 5:712-6.
68. Riddick CA, Ring WL, Baker JR, Hodulik CR, Bigby TD. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. Eur J Biochem 1997; 246:112-8.
69. Barnes NC, Lavins BJ, Miller CF, Cohn J, Perrin V. Safety and tolerance of zafirlukast (Accolate), a new treatment for asthma. Am J Respir Crit Care Med 1997; 155:A663 (abstract).
70. Anonymous. Accolate. Labeling notes possible association with Churg-Strauss syndrome. Formulary 1997; 32:894-5.
71. Awni WM, Wong S, Chu SY et al. Pharmacokinetics of zileuton and its metabolites in patients with renal impairment. J Clin Pharmacol 1977; 37:395-404.
72. Awni WM, Cavanaugh JH, Braeckman RA et al. The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton. Clin Pharmacokinetics 1995; 29 (Suppl. 2):49-61.
73. Savidge RD, Birmingham BK, Morse JL et al. Disposition and metabolism of radiolabeled zafirlukast in the mouse, rat, dog and man. 7th ISSX 1996; 10:391 (abstract).
74. Grimm SW, Stams KR, Aaron EJ. Zafirlukast is a substrate for CYP2C9 and an inhibitor of CYP2C9 and CYP3A in vitro. 7th ISSX 1996; 10:392 (abstract).
75. Vargo DL, Yeh C, Kane CD, Birmingham BK. Effect of zafirlukast on prothrombin time and area under the curve of warfarin. Allergy 1997; 52 (Suppl. 37):184 (abstract).
76. Vargo DL, Suttle AB, Wilkinson LA et al. Effect of zafirlukast on QTc and area under the curve of terfenadine in healthy men. J Clin Pharmacol 1997; 37:870 (abstsract).
77. Suttle AB, Birmingham BK, Vargo DL, Wilkinson LA, Morganroth J. Pharmacokinetics of zafirlukast and terfenadine after coadministration to healthy men. J Clin Pharmacol 1997; 37:870 (abstsract).
78. Machinits JM, Mayer MD, Shet MS, Ferrero JL, Rodriques AD. Indentification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab Dispos 1995; 23:1163-74.
79. Awni WM, Hussein Z, Granneman GR et al. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinetics 1995; 29 (Suppl. 2):67-76.
80. Granneman GR, Braeckman RA, Locke CS et al. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinetics 1995; 29 (Suppl. 2):77-83.
81. Awni WM, Cavanaugh JH, Tzeng TB et al. Pharmacokinetic interactions between zileuton and prednisone. Clin Pharmacokinetics 1995; 29 (Suppl. 2):105-11.